Eton Pharmaceuticals Inc

For the period ended Dec 31, 2023. Filed Mar 14, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 14, 2024

ETON$64.35+14.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets

(in thousands, except share and per share amounts)

	December 31,	December 31,
	2023	2022
Assets
Current assets:
Cash and cash equivalents	$21,388	$16,305
Accounts receivable, net	3,411	1,852
Inventories	911	557
Prepaid expenses and other current assets	1,129	1,290
Total current assets	26,839	20,004
Property and equipment, net	58	72
Intangible assets, net	4,739	4,754
Operating lease right-of-use assets, net	92	188
Other long-term assets, net	12	12
Total assets	$31,740	$25,030
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$1,848	$1,766
Current portion of long-term debt, net of discount	5,380	1,033
Accrued liabilities	9,013	3,662
Total current liabilities	16,241	6,461
Long-term debt, net of discount and including accrued fees	—	5,384
Operating lease liabilities, net of current portion	22	107
Total liabilities	16,263	11,952
Commitments and contingencies (Note 14)
Stockholders’ equity
Common stock, $0.001 par value; 50,000,000 shares authorized; 25,688,062 and 25,353,119 shares issued and outstanding at December 31, 2023 and 2022, respectively	26	25
Additional paid-in capital	119,521	116,187
Accumulated deficit	(104,070)	(103,134)
Total stockholders’ equity	15,477	13,078
Total liabilities and stockholders’ equity	$31,740	$25,030

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.